- CA$0.39m
- CA$7.61m
- CA$0.94m
- 17
- 51
- 16
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.54 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -650.75% | ||
Financial Summary
| Year End 31st Oct | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 1.07 | 0.98 | 1.18 | 1.3 | 0.94 | 2 | 14.4 | 29.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.
Directors
- Jeffrey Kraws NEC (57)
- James Nickerson PRE
- G.F. Anthony CEO
- David Hankinson NVC
- Chris Boland CFO
- Graham Burton CSO
- Aubrey Dan IND
- Paul Mesburis IND (50)
- Last Annual
- October 31st, 2022
- Last Interim
- July 31st, 2023
- Incorporated
- November 1st, 2017
- Public Since
- March 4th, 2004
- No. of Employees
- 12
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
TSX Venture Exchange- Shares in Issue
- 77,694,700
- Address
- 100 Sussex Drive, OTTAWA, K1A 0R6
- Web
- https://avivagen.com/
- Phone
- +1 6137022908
- Contact
- Jeffrey Kraws
- Auditors
- UHY McGovern Hurley LLP
Upcoming Events for VIV
Avivagen Inc Annual Shareholders Meeting
Q2 2024 Avivagen Inc Earnings Release
Q3 2024 Avivagen Inc Earnings Release
Similar to VIV
BioNeutra Global
TSX Venture Exchange
Canyon Creek Food
TSX Venture Exchange
CubicFarm Systems
TSX Venture Exchange
Deveron
TSX Venture Exchange
DLC Holdings
TSX Venture Exchange
FAQ
What is the Avivagen share price?
As of Today at 19:03 UTC, shares in Avivagen are trading at CA$0.01. This share price information is delayed by 15 minutes.
How has the Avivagen share price performed this year?
Shares in Avivagen last closed at CA$0.01 and the price had moved by -92.86% over the past 365 days. In terms of relative price strength the Avivagen share price has underperformed the Toronto Stock Exchange 300 Composite Index by -93.22% over the past year.
What are the analyst and broker recommendations for Avivagen?
The overall consensus recommendation for Avivagen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Avivagen dividend yield?
Avivagen does not currently pay a dividend.
Does Avivagen pay a dividend?
Avivagen does not currently pay a dividend.
When does Avivagen next pay dividends?
Avivagen does not currently pay a dividend.
How do I buy Avivagen shares?
To buy shares in Avivagen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Avivagen?
As of the previous close price of CA$0.01, shares in Avivagen had a market capitalisation of CA$0.39m.
Where are Avivagen shares listed?
Here are the trading details for Avivagen:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: VIV
What kind of share is Avivagen?
Based on an overall assessment of its quality, value and momentum Avivagen is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Avivagen share price forecast for 2024?
The analyst consensus target price for shares in Avivagen is CA$1.38. That is 27500% above the last closing price of CA$0.01.
Analysts covering Avivagen currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.06 for the next financial year.
What is the trend in the Avivagen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Avivagen. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -56.33%.
As of the last closing price of CA$0.01, shares in Avivagen were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Avivagen PE Ratio?
The Avivagen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Avivagen?
Avivagen's management team is headed by:
- Jeffrey Kraws - NEC
- James Nickerson - PRE
- G.F. Anthony - CEO
- David Hankinson - NVC
- Chris Boland - CFO
- Graham Burton - CSO
- Aubrey Dan - IND
- Paul Mesburis - IND